MANCHESTER, N.H., Oct. 08, 2026 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (Nasdaq: ALGM) today announced it plans to release financial results for its second quarter fiscal year 2027 prior to the market open on Thursday, October 29, 2026. Following the press release, Mike Doogue, President and Chief Executive Officer, and Derek D’Antilio, Executive Vice President and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time to discuss the Company’s results and business outlook.
Analysts and investors are invited to join the conference call using the following information:
Second Quarter Fiscal Year 2027 Earnings Conference Call Date: Thursday, October 29, 2026 Time: 8:30 a.m. ET Live Webcast Link: Click Here Dial-in Participant Registration Link: Click Here
Advanced registration is required for dial-in participants. Please complete the linked registration form above to receive a dial-in number and dedicated PIN for accessing the conference call.
A live and archived audio webcast of the conference call will also be accessible for at least 90 days on the Company’s website at www.allegromicro.com/investors in the Events & Presentations section.
About Allegro MicroSystems
Allegro MicroSystems, Inc. is leveraging more than three decades of expertise in magnetic sensing and power ICs to propel electrification, automation, AI data center, and robotics forward with solutions that enhance efficiency, performance and sustainability. Allegro’s commitment to quality drives transformation across industries, reinforcing our status as a pioneer in “automotive-grade” technology and a partner in our customers’ success. For additional information, visit https://www.allegromicro.com/en/.
Contact: Jalene Hoover VP of IR & Corporate Communications Phone: +1 512 751 6526 jhoover@allegromicro.com
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)
1.KEY INFORMATION
(a)Full name of discloser:
Man Group PLC
(b)Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree
Vesuvius plc
(d)If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure
07/10/2026
(f)In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
YES Offeror: RHI Magnestia N.V.
2.POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a)Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
10p ordinary
Interests
Short positions
Number
%
Number
%
(1)Relevant securities owned and/or controlled:
14,581,755
5.87
(2)Cash-settled derivatives:
1,003,291
0.40
499,224
0.20
(3)Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:
15,585,046
6.27
499,224
0.20
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b)Rights to subscribe for new securities (including directors’ and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3.DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a)Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit
10p ordinary
Sale
102,697
4.5252 GBP
(b)Cash-settled derivative transactions
Class of relevant security
Product description e.g. CFD
Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position
(d)Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing e.g. subscription, conversion
Details
Price per unit (if applicable)
4.OTHER INFORMATION
(a)Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
None
(b)Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)the voting rights of any relevant securities under any option; or (ii)the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
None
(c)Attachments
Is a Supplemental Form 8 (Open Positions) attached?
NO
Date of disclosure:
08/10/2026
Contact name:
Graham Keene
Telephone number:
+44 20 7144 2259
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Order includes Net Pods and integration support to add net interception capabilities to a drone interceptor platform designed for critical infrastructure and strategic site protection
KFAR SABA, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (“ParaZero” or the “Company”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced receipt of an initial order from a new U.S.-based defense manufacturer for DefendAir Net Pods and related integration support.
The customer develops drone detection and interception technologies and holds contracts to protect critical infrastructure and strategic sites. The order supports the integration of ParaZero’s DefendAir Net Pods into the customer’s drone interceptor platform, adding non-explosive net interception alongside its existing hit-to-kill capability.
The integration is intended to connect the customer’s detection and tracking capabilities with DefendAir’s physical interception technology, providing an additional engagement option for countering hostile drones. ParaZero will supply Net Pods and technical support for the integration process.
The initial order expands ParaZero’s footprint in the U.S. counter-UAS market and reflects demand for adaptable interception technologies that can be integrated into third-party defense platforms.
“Protecting critical infrastructure and strategic sites requires the ability to detect a drone threat and act to stop it,” said Ariel Alon, Chief Executive Officer of ParaZero. “This initial order expands our U.S. footprint through a new platform integration, adding DefendAir’s non-explosive net interception to the customer’s existing capabilities. Our Net Pods and integration support provide the foundation for that work.”
DefendAir uses net-based physical interception to stop hostile drones at the last defensive layer. Its Net Pods support integration into multiple platforms, enabling manufacturers to incorporate ParaZero’s interception technology into their counter-UAS systems.
The DefendAir product family will be showcased at ParaZero’s booth at the AUSA Annual Meeting in Washington, D.C., October 12–14, within the SIBAT (Israeli Ministry of Defense) National Defense Pavilion, Booth #739.
About ParaZero Technologies
ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry.
Founded in 2014 by aviation professionals and drone industry veterans, ParaZero develops intelligent, mission-ready technologies for defense and advanced aerial applications.
The Company’s DefendAir product family provides a controlled, non-explosive, net-based physical interception capability designed for integration across personal, mobile, autonomous and fixed-site Counter-UAS systems.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding ParaZero’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the proposed integration of DefendAir Net Pods into the customer’s drone interceptor platform; the anticipated capabilities, development, testing and potential applications of the integrated platform; the Company’s provision of integration support; the potential benefits of the integration; the potential demand for and broader adoption of DefendAir by defense manufacturers and system integrators; the Company’s expectation that the order may expand its footprint in the U.S. counter-UAS market; its belief that the order reflects demand for adaptable interception technologies; and the potential for DefendAir technologies to be integrated into third-party defense platforms; and the planned showcase of the DefendAir product family at the AUSA Annual Meeting. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the SEC on March 26, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.
General Fusion completes the first major technical milestone of its LM26 program with world-first fusion result co-authored by the UKAEA
General Fusion, UKAEA Announce Magnetized Target Fusion Milestone
General Fusion completes the first major technical milestone of its LM26 program with world-first fusion result co-authored by the UKAEA
General Fusion’s 1 keV Plasma Compression
VANCOUVER, British Columbia and OXFORD, England, Oct. 08, 2026 (GLOBE NEWSWIRE) — General Fusion Group Ltd. (NASDAQ: GFUZ) (“General Fusion” or the “Company”), a leading fusion company, has achieved a historic compressional plasma heating result with its large-scale Lawson Machine 26 (“LM26”) demonstration. Using Magnetized Target Fusion (“MTF”), the Company reached electron temperatures exceeding 12 million degrees Celsius – more than 1 keV. The results were co-published by the UK Atomic Energy Authority (“UKAEA”), the UK’s national fusion laboratory, and measured using gold-standard Thomson scattering methods.
Only a few fusion companies have surpassed the industry-recognized milestone of 1 keV, all using other fusion approaches. This world-first result for General Fusion’s MTF approach marks a measurable step forward for the Company in its aim to deliver baseload, economical clean power from fusion energy.
The 1.1 keV electron heating (12.6 million degrees Celsius) result was measured just prior to peak compression and is detailed in a technical paper co-authored by UKAEA that is being concurrently posted on General Fusion’s website and submitted for peer review.
Scientific Progress
As a technology, General Fusion’s MTF aims to achieve fusion in a practical and economical way, using a liquid metal wall which enables the use of existing materials and, ultimately, durable machines. It also allows the Company’s design to avoid superconducting magnets and high-powered lasers. The approach is designed to solve significant long-standing barriers to commercializing fusion energy at a time when electricity demand is surging, and nations around the world are racing to bring fusion power to the grid.
General Fusion’s LM26 program is designed to reach key technical milestones on the path to a first-of-a-kind fusion plant in the next decade. LM26 is the first fusion machine in the world to achieve 1 keV with low-speed compression. Using MTF, the Company heats magnetically confined plasma through compression in milliseconds as compared to other types of plasma compression technologies in microseconds or nanoseconds. In LM26, this compression is achieved with a solid metal wall, rather than high-powered lasers or other methods operating in physical extremes. Achieving 1 keV through practical, low-speed compression is unique to General Fusion and is a key step toward its ultimate commercial approach.
Upcoming LM26 Milestones
General Fusion is advancing its LM26 program as part of its phased commercialization plan. Upgrades to the LM26 machine are now underway to support higher plasma compression ratios ahead of the Company’s next targeted 10 keV milestone. The LM26 program will then advance toward the Lawson criterion, the combination of temperature, density, and energy confinement time required for net fusion energy in the plasma. This program is designed to de-risk the path to practical fusion power and support the Company’s goal to begin operating a first-of-a-kind plant around 2035.
UKAEA Expertise in Fusion Diagnostics
The findings were made possible through UKAEA’s expertise in plasma diagnostics. Drawing on decades of experience operating fusion facilities such as the Joint European Torus (JET) and flagship machine, MAST Upgrade, UKAEA has internationally recognised expertise in plasma diagnostics, the systems used to measure and understand the behaviour of fusion plasmas.
Measuring plasma temperature is a complex process. In fusion research, scientists use a laser-based technique called Thomson scattering to do this. They shine a laser through the plasma and analyse how the light scatters from the particles inside it. This lets them accurately measure how hot the plasma is, without disturbing it. This way of measuring plasma dates back to 1969 when UKAEA scientists collaborated with Russian researchers to record fusion temperatures above 10 million degrees Celsius. This breakthrough reshaped fusion research worldwide and established UKAEA as a leader in plasma diagnostics.
Measuring plasma conditions on LM26, and applying Thomson scattering, presented a significant technical challenge. The plasma is enclosed within a metal liner and compressed to a very small volume, severely limiting diagnostic access and visibility. Despite these constraints, diagnostic specialists from UKAEA and General Fusion jointly designed and commissioned a Thomson scattering system that successfully measured the plasma near peak compression conditions. One of the key components of the diagnostic system was a state-of-the-art polychromator designed and built by UKAEA at its newly established Diagnostic Innovation Centre of Excellence (DICE) facility at the Culham Campus in the UK. For General Fusion, the diagnostic provided critical measurements of plasma temperature and performance. This is one example of how UKAEA’s capability is helping to support the development of fusion technologies and delivering advanced diagnostic solutions for fusion programmes around the world.
Global Collaboration Advancing the Path to Commercialization
General Fusion has spent more than two decades developing its fusion technology in Canada, with support from the Government of Canada’s Strategic Response Fund and other programs that have been instrumental to the Company’s progress. The Company has also advanced its technology with leading fusion research organizations worldwide, including a long-standing collaboration with UKAEA to optimize diagnostic systems. The General Atomics Energy Group is also advising on the diagnostic system required for the Company’s next milestone.
Quotes
“General Fusion has a two-decade track record of achieving industry-first milestones in Magnetized Target Fusion supported by a substantial body of peer-reviewed scientific literature. We built LM26 to achieve important technical milestones that will help get us to a first-of-a-kind plant in the next decade, and step-by-step we are advancing on this path. Congratulations to our incredible team and thank you to UKAEA for our longstanding collaboration. Together, we’ve achieved an industry-defining result on the path to commercializing cost-effective, practical fusion energy.”
— Greg Twinney, Chief Executive Officer, General Fusion
“Achieving a plasma electron temperature of over 1 keV marks an important milestone for General Fusion since achieving hot electrons is a necessary step for proving fusion confinement concepts. This achievement reflects the tangible progress being made by General Fusion and others across a diverse set of fusion approaches in the private sector, while the collaboration with UKAEA, contributing its specialist expertise, highlights the value of robust public-private partnerships in broadly advancing fusion and sharing scientific results. It also continues a great tradition of international scientific collaboration: in 1969, a UK team used the then-new laser-based Thomson scattering technique to verify 1 keV electrons in a Russian tokamak, helping to establish what became the standard magnetic confinement concept. We now look forward to the outcome of the formal peer review process and the publication of the paper in Review of Scientific Instruments.”
— Professor Dennis Whyte, Chief Executive Officer, United Kingdom Atomic Energy Authority
About General Fusion
General Fusion (NASDAQ: GFUZ) is a fusion technology development company. The Company aims to deliver economical, carbon-free fusion energy through its practical Magnetized Target Fusion (“MTF”) technology, an engineering-driven approach to fusion energy. General Fusion’s commercialization program is anchored by LM26, the world’s first commercially relevant-scale MTF demonstration machine. The Company is working toward the commercial deployment of fusion power in the mid-2030s. General Fusion is the first publicly listed fusion company and TIME’s No. 1 GreenTech Company of 2026. For more information, visit generalfusion.com or follow General Fusion on LinkedIn, YouTube, and X.
About the United Kingdom Atomic Energy Authority
Who we are
The United Kingdom Atomic Energy Authority (UKAEA) is the UK’s national fusion energy research organisation. We are an executive non-departmental public body of the Department for Energy Security and Net Zero (DESNZ).
The work we do
UKAEA’s mission is to lead the delivery of sustainable fusion energy to maximise scientific and UK economic benefit. We do this by being technical experts, partnering with companies and the international research community.
At the core of UKAEA’s efforts is the operation of world-leading facilities that build a comprehensive knowledge base for fusion energy. By addressing and solving the challenges across the full lifecycle of fusion, and integrating solutions from various disciplines, we establish technical centres of excellence that serve as the foundation for future fusion power plant programmes.
UKAEA collaborates with its partners to develop fusion power plants by providing access to our skills, facilities and expertise. UKAEA owns UKFE Ltd on behalf of the UK government. Through UKFE Ltd, we’re spearheading the STEP Fusion programme to design and build the UK’s first prototype fusion energy power plant in Nottinghamshire.
To grow the fusion ecosystem, UKAEA focuses on cultivating skilled talent, growing the fusion industry and creating ‘innovation clusters’. We actively seek opportunities to advance fusion technologies and communicate its vast potential to stakeholders and the public alike to accelerate fusion energy’s future – the energy of tomorrow we need today.
If you are based in North America, you may also leave a toll-free voicemail at +1 (833) 717-1519. Callers outside North America can reach us at +1 (236) 253-6968.
This communication includes “forward-looking statements” within the meaning of the U.S. federal securities laws and “forward looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). All statements other than statements of historical facts contained herein are forward-looking statements. Any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are also forward-looking statements. In some cases, you can identify forward-looking statements by words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “strategy,” “future,” “opportunity,” “may,” “target,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “preliminary,” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include, without limitation, statements regarding its ability to commercialize Magnetized Target Fusion (“MTF”) or any other fusion technology on its expected timeline or at all; statements regarding the current and expected results of the LM26 program, the Company’s plan to operate a first-of-a-kind plant around 2035; statements regarding the expected market opportunity for fusion energy, as well as any information concerning possible or assumed future results of operations or financial position of the Company.
These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements involve a number of risks, uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the technical results disclosed herein are not accepted or validated by the broader scientific community (including that the peer review process is unsuccessful); the risk that prior results are not successfully repeated on a larger scale; the risk that the scientific and technical assumptions underlying the results described herein prove to be incorrect; the risk that our relationship with UKAEA and others deteriorates or terminates, the risk that recent technical results do not prove to be as significant to the operation of LM26 as expected; the risk that the anticipated cost of funding the LM26 program across several planned technical milestones through the end of 2028 is greater than anticipated and additional capital needed by the Company may not be raised on favorable terms, or at all, including as a result of the restrictions agreed to in connection with the private placement the Company closed on July 10, 2026; the risk of adverse changes in general economic, financial market and geopolitical conditions, including conditions affecting capital markets and the clean energy sector; the risk that we are unable to develop, demonstrate and commercialize MTF technology on the expected timeline or at all, including any failure to achieve the balance of technical objectives of the LM26 program; the risk that we are unable to begin operating a first-of-a-kind plant around 2035, or at all; the risk that fusion energy does not gain public acceptance, the risk that the scientific and technical assumptions upon which the Company’s MTF technology is based do not prove to be correct, risks associated with the Company’s status as a development-stage company with a history of losses, no revenue from commercial fusion energy operations and no assurance of achieving profitability; the risk that our competitors develop viable fusion technology sooner than we do, the risk of supply chain disruptions, the risk that key technical material and service inputs may not be available when required on reasonable terms or at all, the risk that we are unable to attract and retain qualified personnel with highly technical expertise, the risk that we are subject to negative publicity, the risk that our assessment of the total addressable market for fusion energy is incorrect, the risk of changes in the laws and regulations governing the Company’s research and development activities and in the regulation of fusion energy generally; the risk of fluctuations in foreign currency exchange rates, particularly fluctuations in the Canadian dollar relative to the U.S. dollar; the risk that the Company is unable to complete and successfully integrate any future acquisitions; the risk of increased competition from other fusion energy companies and from other clean energy, conventional energy and energy storage technologies; the risk of accidents, earthquake, fires, floods and other natural disasters, the risk that our information technology fails, the risk that our operating expenses are materially higher than forecast, the risk that we are unable to remediate material weaknesses in our internal controls or identify additional material weaknesses in the future, the risk that we are unable to adequately protect or enforce our intellectual property rights, the risk of third party claims that we are infringing or violating another person’s intellectual property rights, the risk that our intellectual property applications are not granted, the risk of a cyber event or privacy breach resulting in an interruption in operations or financial loss, the risk that the trading in our securities may be volatile due to limited volume and the release of a substantial number of Subordinate Voting Shares from a lock-up expiring 180 days after the closing date of our business combination in July 2026; the risk of substantial dilution upon a reduction in the exercise or conversion price of the Multiple Voting Shares and PIPE warrants issued in July 2026 in accordance with the terms thereof; the effectiveness of our internal controls and disclosure controls and procedures; risks arising as a result from the limited experience of certain members of our management team in operating a public company; the risk that the period during which we will qualify as an emerging growth company under the JOBS Act is reduced; and the risk of litigation, governmental or regulatory proceedings, investigations or inquiries.
The foregoing list is not exhaustive, and there may be additional risks that the Company does not know or currently believes are immaterial. You should carefully consider the foregoing factors, any other factors discussed herein and in the other filings by the Company with the U.S. Securities and Exchange Commission including those described under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.
These forward-looking statements are based on a number of estimates and assumptions that we believe are reasonable when made including but not limited to: that none of the risks identified above materialize; that there are no unforeseen changes to economic and market conditions, and that no significant events occur outside the ordinary course of business.
In addition, these statements reflect the expectations, plans, and forecasts of the Company’s management as of the date of this communication; subsequent events and developments may cause their assessments to change. While the Company may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so, unless required by applicable securities laws. Accordingly, undue reliance should not be placed upon these statements.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this communication, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.
Growing Multifamily Demand Highlights Opportunity to Deliver Greater Convenience for Residents and a Distinctive, Highly Visible Amenity for Property Owners
LAS VEGAS, Oct. 08, 2026 (GLOBE NEWSWIRE) — VenHub Global, Inc. (NASDAQ: VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced plans for the first deployment of its Smart Store autonomous retail platform at Penn Lofts, a new 59-unit multifamily development in Bend, Oregon.
The deployment represents an important expansion of the VenHub Smart Store platform into the multifamily residential market, where the Company is seeing growing demand from developers and property owners seeking new ways to enhance the resident experience and differentiate their communities. By bringing convenient access to everyday products and essentials directly to where people live, VenHub aims to create value for both residents and multifamily owners.
For residents, a VenHub Smart Store offers the convenience of on-site shopping without a separate trip to a traditional store. For developers, owners and property managers, it provides a distinctive amenity that can strengthen a property’s appeal, support resident satisfaction and retention, and add a tangible point of differentiation to leasing and marketing efforts. As a highly visible feature within a community, a VenHub Smart Store can also help owners showcase their investment in convenience, technology and the resident experience.
VenHub has worked closely with the developer to integrate the VenHub Smart Store directly into the design and plans for the new community. Rather than being added to the property as an afterthought, the VenHub Smart Store is being incorporated as a core resident amenity, allowing it to fit seamlessly within the development while providing convenient access to everyday products and essentials.
The deployment also demonstrates the flexibility of VenHub’s autonomous retail platform across residential properties of varying sizes. VenHub can offer various configurations of its Smart Store format including smaller-sized formats that are well suited to serve communities such as this 59-unit development and full-size stores capable of serving a greater number of residents and a broader range of products.
VenHub expects the multifamily residential sector will serve as a significant long-term growth opportunity and intends to make autonomous retail a valuable amenity for apartment communities, deploying VenHub Smart Stores based on the size, density and needs of each community. This first deployment at Penn Lofts can serve as a test case for future deployments in other multifamily developments as the Company addresses this attractive market opportunity.
“Multifamily residential communities represent a significant growth opportunity for VenHub, and we are seeing increasing demand from developers and property owners who recognize the value of bringing autonomous retail directly into their communities,” said Shahan Ohanessian, Founder and CEO of VenHub. “Residents increasingly expect convenience to be built into where they live. Our flexible platform helps owners meet that expectation with a distinctive, highly visible amenity that adds value for residents and helps properties stand out – from smaller communities to larger multifamily developments. Penn Lofts is an ideal first deployment to demonstrate how our technology can be thoughtfully integrated into a community from the beginning.”
Penn Lofts is being developed as a modern residential community in Bend, Oregon. The development team worked with VenHub during the planning process to identify a location and configuration that makes the store a natural part of the property and easily accessible to residents.
VenHub plans to build on the Penn Lofts deployment as it expands into the multifamily sector. The Company believes its autonomous retail platform can provide developers, apartment owners and property managers with a new type of resident amenity while creating a significant new deployment channel for VenHub.
The company is actively evaluating additional multifamily opportunities and expects to provide updates regarding additional properties and deployments as its multifamily strategy develops. Developers, apartment owners and property managers interested in collaborating with VenHub should contact the Company at hello@venhub.com or visit https://www.venhub.com/partners-and-opportunities/become-a-smart-store-owner.
About VenHub VenHub Global, Inc. (NASDAQ: VHUB) is focused on fully autonomous Smart Store technology. The Company develops automated retail solutions intended to enable convenient, unattended retail experiences across a range of locations and customer environments. VenHub’s Smart Store platform is designed to support scalable deployment, 24/7 product availability, and retail access in locations where a traditional staffed store may not be feasible. For more information, visit www.venhub.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include, but are not limited to, statements regarding the planned deployment of a VenHub Smart Store at Penn Lofts in Bend, Oregon; the integration of the Smart Store into the development’s design and resident amenities; the anticipated functionality, accessibility, convenience, product availability and other benefits of the store; the suitability of different Smart Store configurations for residential communities of varying sizes and densities; the potential for the Penn Lofts deployment to serve as a test case for future multifamily deployments; the size and potential of the multifamily residential market as a long-term growth opportunity and new deployment channel for VenHub; and the Company’s plans to evaluate additional properties, expand deployments and provide future updates.
Words such as “anticipate,” “believe,” “can,” “could,” “designed,” “expect,” “intend,” “may,” “opportunity,” “plan,” “potential,” “should,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements are based on the Company’s current expectations, assumptions and information available as of the date of this release and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied.
Such factors include, but are not limited to: changes in the construction schedule, design, completion or occupancy of Penn Lofts; the ability of VenHub and the developer to finalize and execute installation and operating arrangements; site readiness, space constraints, utility and connectivity requirements, and necessary permits and approvals; the availability and timely delivery of equipment, components and inventory; the performance, reliability, security and maintenance of the Smart Store technology; the ability to establish suitable product assortments and effective replenishment and service arrangements; resident adoption, purchasing activity and demand; acceptance of autonomous retail amenities by developers, property owners and property managers; the costs and economic viability of individual deployments; the availability of financing and other resources to support deployment and expansion; competition and general economic and real estate market conditions; applicable regulatory and contractual requirements; and other risks and uncertainties described in VenHub’s filings with the U.S. Securities and Exchange Commission.
Forward-looking statements speak only as of the date of this release. VenHub undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
Media and investor contacts
VenHub Global, Inc. Alyssa Barry Director of Investor Relations and Public Relations Alyssa@VenHub.com
Richard Land Alliance Advisors vhub@allianceadvisors.com
TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) — DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) (“DPM” or “the Company”) today announced preliminary production results for the three and nine months ended September 30, 2026.
“We continue to deliver strong operating performance, producing 97,000 gold equivalent ounces in the third quarter, positioning DPM to achieve the high-end of our production guidance for 2026,” said David Rae, President and CEO of DPM Metals.
“The ramp-up of Vareš continues to progress ahead of our expectations and the mine is now expected to exceed its 2026 production guidance – an achievement that demonstrates our strong operating capabilities.
“Before year-end, we plan to start development of the twin declines for the Wedge Zone, which is expected to add near-term production and mine life at Chelopech. Combined with our ongoing exploration success at Dumitru Potok and Brevene Porphyry South, we are building a platform for high-margin growth to deliver strong returns for our shareholders.
“We continue to invest in these high-return organic growth opportunities while returning capital to shareholders, buying back nearly $150 million of shares year-to-date, reflecting our confidence and excitement for our organic growth potential.”
Preliminary Third Quarter 2026 Production Highlights
Preliminary results for the third quarter of 2026 are provided below:
Unit
Chelopech
Ada Tepe
Vareš
Consolidated
Ore processed
Kt
530
38
143
711
Metals contained in concentrate produced
Gold
Koz
41
2
10
53
Silver
Koz
46
1
887
934
Copper
Mlbs
5
–
2
7
Zinc
Mlbs
–
–
28
28
Lead
Mlbs
–
–
17
17
Gold equivalent ounces (“GEO”)1
Koz
50
2
45
97
Payable metals in concentrate sold
Gold
Koz
37
2
8
47
Silver
Koz
42
1
824
867
Copper
Mlbs
5
–
1
6
Zinc
Mlbs
–
–
16
16
Lead
Mlbs
–
–
12
12
GEO1
Koz
45
2
30
77
The Company uses conversion ratios for calculating GEO for its silver, copper, zinc and lead production and sales, which are calculated by multiplying the volumes of metal produced or sold, as applicable, by the respective average market metal prices for the quarter, and dividing the resulting figure by the average market gold price. See section titled “Gold Equivalent Calculation” on page 4 for the average market metals prices used in the calculation of third quarter gold equivalent production.
Preliminary results for the first nine months of 2026 are provided below:
Unit
Chelopech
Ada Tepe
Vareš
Consolidated
Ore processed
Kt
1,586
403
339
2,328
Metals contained in concentrate produced
Gold
Koz
116
25
25
166
Silver
Koz
379
17
2,842
3,238
Copper
Mlbs
20
–
4
24
Zinc
Mlbs
–
–
52
52
Lead
Mlbs
–
–
35
35
GEO1
Koz
149
25
109
283
Payable metals in concentrate sold
Gold
Koz
105
25
17
147
Silver
Koz
346
14
2,202
2,562
Copper
Mlbs
18
–
1
19
Zinc
Mlbs
–
–
30
30
Lead
Mlbs
–
–
23
23
GEO1
Koz
135
26
69
230
The Company uses conversion ratios for calculating GEO for its silver, copper, zinc and lead production and sales, which are calculated by multiplying the volumes of metal produced or sold, as applicable, by the respective average market metal prices for the quarter, and dividing the resulting figure by the average market gold price. See section titled “Gold Equivalent Calculation” on page 4 for the average market metals prices used in the calculation of the first nine months of 2026 gold equivalent production.
Operating Highlights
As a result of strong year-to-date performance, DPM now expects to achieve the high end of its gold equivalent production guidance for the year.
Vareš produced approximately 45,000 GEO in the third quarter, in line with the planned ramp-up of the mine to full production and reflecting stronger than expected grades. Construction of the second tailings filter and paste backfill plant are nearing completion and are expected to begin commissioning in November and December, respectively.
Overall, the Vareš ramp-up is proceeding on plan, and DPM expects to achieve the full production run-rate of 850,000 tonne per annum by the end of 2026. Varesš is expected to exceed the high end of its 2026 gold equivalent production range.
On August 10, 2026, DPM declared commercial production at Vareš. Gross operating costs at Vares will be included in its all-in sustaining cost from that date forward.
Refer to the Company’s news release dated October 1, 2026, for information with respect to the recent decision of the Constitutional Court in Bosnia and Herzegovina and the “Cautionary Note Regarding Forward Looking Information” section of this news release.
Chelopech produced approximately 50,000 GEO in the third quarter, which was in line with plan, and Chelopech is on-track to achieve its production guidance for 2026.
DPM has continued to advance the high-grade Wedge Zone prospect as a near-term opportunity, which is expected to grow production and extend mine life at Chelopech commencing in late 2028. The Company is on track to complete an initial Wedge Zone Mineral Resource estimate by year-end and has advanced engineering to proceed with the development of twin declines to the Wedge Zone, which is expected to commence during the fourth quarter of 2026. The Wedge Zone is expected to begin contributing to Chelopech’s production in late 2028.
Ada Tepe produced approximately 2,000 GEO in the third quarter, as the process plant concluded operations on July 15, 2026. Dismantling and refurbishing of certain processing facilities commenced, in preparation for the Čoka Rakita project, which is expected to commence construction in early 2027.
Return of Capital to Shareholders
During the third quarter of 2026, DPM repurchased 1,860,000 common shares at an average price of US$40.23 (Cdn$56.35) per share for a total cost of approximately US$74.8 million under its Normal Course Issuer Bid. Year-to-date, the Company has repurchased 4,003,348 common shares at an average price of US$37.36 (Cdn$51.97) per share for a total of approximately US$149.6 million.
Since 2021, DPM has repurchased a total of 33.6 million shares at an average price of C$16.71, which represents approximately 18% of the weighted average number of shares outstanding over that period.
As previously announced in July 2026, DPM will pay a quarterly dividend of US$0.04 per share on October 15, 2026, to shareholders of record on September 30, 2026.
Timing of Third Quarter 2026 Operating and Financial Results
The Company plans to release its third quarter 2026 operating and financial results after market close on Thursday, November 12, 2026. The news release, Management’s Discussion and Analysis (“MD&A”) and condensed interim consolidated financial statements will be posted on SEDAR+ at www.sedarplus.ca and on the Company’s website at www.dpmmetals.com.
On Friday, November 13, 2026, at 9 AM EST, DPM will host a conference call and audio webcast to discuss the results, followed by a question-and-answer session. To participate via conference call, register in advance at the link in the following table to receive the dial-in information as well as a personalized PIN code to access the call.
The Company uses conversion ratios for calculating GEO for its silver, copper, zinc and lead production and sales, which are calculated by multiplying the volumes of metal produced or sold, as applicable, by the respective assumed metal prices, and dividing the resulting figure by the assumed gold price. The consolidated total GEO reported may include minor quantities of other metals that are not considered material.
GEO produced and sold for the third quarter and first nine months of 2026 and DPM’s 2026 guidance are based on the following metal prices:
Gold ($/oz.)
Silver ($/oz.)
Copper ($/lb.)
Zinc ($/lb.)
Lead ($/lb.)
Third quarter of 2026 average market metal prices
4,270
62.73
6.40
1.74
0.84
First nine months of 2026 average market metals prices
4,554
73.52
6.09
1.59
0.87
2026 guidance assumption
4,200
50.00
5.00
1.30
0.90
For more information regarding DPM’s 2026 guidance and three-year outlook, refer to the MD&A for the three months ended March 31, 2026, issued on May 5, 2026, available on at www.sedarplus.ca and at www.dpmmetals.com.
Technical Information
The technical and scientific information in this news release has been reviewed and approved by Ross Overall, Director, Corporate Technical Services, of DPM, who is a Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects, and not independent of the Company.
About DPM Metals Inc.
DPM Metals Inc. is a Canadian-based international gold mining company with operations and projects located in Bulgaria, Bosnia and Herzegovina, Serbia and Ecuador. Our strategic objective is to become a mid-tier precious metals company, which is based on sustainable, responsible and efficient gold production from our portfolio, the development of quality assets, and maintaining a strong financial position to support growth in mineral reserves and production through disciplined strategic transactions. This strategy creates a platform for robust growth to deliver above-average returns for our shareholders. DPM trades on the Toronto Stock Exchange (symbol: DPM) and the Australian Securities Exchange as a Foreign Exempt Listing (symbol: DPM).
For further information please contact:
Jennifer Cameron Director, Investor Relations Tel: (416) 219-6177 jcameron@dpmmetals.com
This news release contains “forward looking statements” or “forward looking information” (collectively, “Forward Looking Statements”) that involve a number of risks and uncertainties. Forward Looking Statements are statements that are not historical facts and are generally, but not always, identified by the use of forward looking terminology such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “outlook”, “intends”, “anticipates”, “believes”, or variations of such words and phrases or that state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms or similar expressions. The Forward Looking Statements in this news release relate to, among other things: updated guidance for Vareš, the expected timing of commissioning of paste backfill plant and second tailings filter and expectations with respect to the ramp-up and full production run-rate at Vareš; expected rates of production at the Company’s operating properties; the Company’s future business plans, objectives, and strategy, including, without limitation, meeting its targeted annual rates of production from its operating mines; anticipated steps in the development of the Wedge Zone prospect at Chelopech, the timing thereof, and their anticipated impact on future rates of production and mine life; anticipated steps in the development of the Čoka Rakita project and the timing thereof, including the timing for commencement of construction; statements with respect to outlook and guidance previously provided by the Company; the Company’s intentions with respect to repurchases of shares under its Normal Course Issuer Bid; timing and amounts of dividends; and the anticipated timing for the release of the Company’s financial and operational results for the three and nine month periods ended September 30, 2026. Forward Looking Statements are based on certain key assumptions and the opinions and estimates of management, as of the date such statements are made, and they involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any other future results, performance or achievements expressed or implied by the Forward Looking Statements. In addition to factors already discussed in this news release, such factors include, among others, fluctuations in metal prices and foreign exchange rates; in respect of the Constitutional Court decision announced in the Company’s news release dated October 1, 2026 ordering a review by the relevant authorities of certain acts reflecting state-owned forests and forestry land, including the Concession Agreement and its annexes for the Vareš operation and other instruments related thereto, there are uncertainties with respect to such review and the outcome thereof on DPM’s Concession Agreement and other instruments, as well as uncertainties with respect to DPM being able to be successful in its engagement and next steps to protect its rights, and the outcome of such review may affect the guidance and other expectations for Vareš, its operations, and other matters discussed above, which assume that DPM’s Concession Agreement and other instruments will remain unaffected (see Company’s news release dated October 1, 2026 for more information); risks arising from the current economic environment and the impact on operating costs and other financial metrics, including risks of recession; the commencement, continuation or escalation of geopolitical crises and armed conflicts and their direct and indirect effects on the operations of DPM; changes in laws and regulations, or judicial interpretations thereof, including with respect to taxes, and the Company’s ability to successfully obtain all necessary permits and other approvals required to conduct its operations; risks arising from counterparties being unable to or unwilling to fulfill their contractual obligations to the Company; the speculative nature of mineral exploration, development and production, including changes in mineral production performance, exploitation and exploration results; the Company’s dependence on its operations at Chelopech and Vareš; changes in tax and tariff regimes in the jurisdictions in which the Company operates or which are otherwise applicable to the Company’s business, operations, or financial condition; possible inaccurate estimates relating to future production, operating costs and other costs for operations; possible variations in ore grade and recovery rates; inherent uncertainties in respect of conclusions of economic evaluations, economic studies and mine plans; uncertainties with respect to the results of technical studies of the Company’s exploration and development projects and the results thereof; the Company’s dependence on continually developing, replacing and expanding its mineral reserves; uncertainties and risks inherent to developing and commissioning new mines into production, which may be subject to unforeseen delays; risks related to the possibility that future exploration results will not be consistent with the Company’s expectations, that quantities or grades of reserves will be diminished, and that resources may not be converted to reserves; risks associated with the fact that certain of the Company’s initiatives are still in the early stages and may not materialize; changes in project parameters, including schedule and budget, as plans continue to be refined; risks related to the financial results of operations, changes in interest rates, and the Company’s ability to finance its operations; the impact of global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future cash flows; uncertainties inherent with conducting business in foreign jurisdictions where corruption, civil unrest, political instability and uncertainties with the rule of law may impact the Company’s activities; accidents, labour disputes and other risks inherent to the mining industry; failure to achieve certain cost savings; risks related to the Company’s ability to manage environmental and social matters, including risks and obligations related to closure of the Company’s mining properties; risks related to climate change, including extreme weather events, resource shortages, emerging policies and increased regulations related to greenhouse gas emission levels, energy efficiency and reporting of risks; land reclamation and mine closure requirements, and costs associated therewith; the Company’s controls over financial reporting and obligations as a public company; delays in obtaining governmental approvals or financing or in the completion of development or construction activities; opposition by social and non-governmental organizations to mining projects; uncertainties with respect to realizing the anticipated benefits from the development of the Company’s exploration and development projects; cyber-attacks and other cybersecurity risks; competition in the mining industry; exercising judgment when undertaking impairment assessments; claims or litigation; limitations on insurance coverage; changes in values of the Company’s investment portfolio; employee relations, including unionized and non-union employees, and the Company’s ability to retain key personnel and attract other highly skilled employees; ability to successfully integrate acquisitions or complete divestitures; disputes and challenges with respect to land title; volatility in the price of the common shares of the Company; potential dilution to the common shares of the Company; damage to the Company’s reputation due to the actual or perceived occurrence of any number of events, including negative publicity with respect to the Company’s handling of environmental matters or dealings with community groups, whether true or not; risks related to holding assets in foreign jurisdictions; conflicts of interest between the Company and its directors and officers; the timing and amounts of dividends; there being no assurance that the Company will purchase additional common shares of the Company under the Normal Course Issuer Bid, as well as those risk factors discussed or referred to in the MD&A, the Company’s most recent Annual Information Form in any other documents filed from time to time with the securities regulatory authorities in all provinces and territories of Canada and available on SEDAR+ at www.sedarplus.ca . Any of the risks discussed herein and in any other documents filed from time to time with the securities regulatory authorities by the Company may result in a material adverse effect on the Company. The reader has been cautioned that the foregoing list is not exhaustive of all factors which may have been used. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in Forward Looking Statements, there may be other factors that cause actions, events or results not to be anticipated, estimated or intended. There can be no assurance that Forward-Looking Statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company’s Forward Looking Statements reflect current expectations regarding future events and speak only as of the date hereof. Unless required by securities laws, the Company undertakes no obligation to update Forward Looking Statements if circumstances or management’s estimates or opinions should change. Accordingly, readers are cautioned not to place undue reliance on Forward Looking Statements.
Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)
Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements. The published patent application covers the use of 3-Methylmethcathinone (“3-MMC”) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical compositions comprising 3-MMC. The application also includes claims for combinations of 3-MMC with N-acylethanolamines, notably Palmitoylethanolamide (“PEA”, a compound with established anti‑inflammatory and neuroprotective properties.
These patent applications are part of the ongoing collaboration between Clearmind and NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage biotech company. Through this partnership with NeuroThera, PEA technology is integrated into Clearmind’s psychedelic-derived therapeutic programs. “
Our strategy is to build robust intellectual property protection around our novel therapeutic platforms and their broad potential across neurological disorders,” said Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind. “The publication of the patent application in Japan and strengthens our global IP position for our 3-MMC-based approach to dyskinesia, including its combination with PEA.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its strategy is to build robust intellectual property protection around its novel therapeutic platforms and their broad potential across neurological disorders and strengthening our global IP position. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — Trekor Metals Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) (“Trekor” or the “Company”) is pleased to announce third quarter total production of 41 million pounds of copper from its 100%-owned Gibraltar mine and Florence Copper production facility.
Gibraltar produced 34 million pounds of copper and 380 thousand pounds of molybdenum in the quarter. The Connector Pit continued to deliver strong grades which, in addition to an increase in mill throughput and improved SX/EW plant performance, drove a 12% increase in quarterly production. Copper sales from Gibraltar totalled 31 million pounds in the period.
The Florence Copper ramp-up continued in the third quarter with steady monthly production growth. Total copper cathode production was seven million pounds, a 36% increase over the prior period. Sales for the quarter were seven million pounds.
Stuart McDonald, President & CEO of Trekor, commented, “Solid progress on the Florence Copper ramp- up continued in the third quarter with no wellfield performance issues of any significance. Initial flow rates across the wellfield continue to exceed expectations, and work is ongoing to optimize the balance between wellfield flows and PLS grade. The SX/EW plant has been operating very well, producing high-quality copper cathode with no impurities, and operated for several days last week at design capacity without issue. The one area where progress remains behind our initial plan is the wellfield expansion. Drilling rates have improved in recent months, but we are still about three months behind our original plan. We are now expecting 25 to 28 million pounds of copper production in 2026. Wells recently brought online, together with those expected to come online shortly, are anticipated to support a significant increase in cathode production, completing the ramp-up to full production capacity in early 2027.”
“Our Gibraltar mine had another strong quarter of operating performance, as higher grade ore was mined from the bottom of the Connector Pit. The transition back into more complex ore began later in the third quarter which impacted recoveries as expected. In the fourth quarter we expect lower grades and recoveries as mining transitions back to the upper benches of the Connector Pit. Based on production through three quarters, we now expect Gibraltar to produce 115 to 120 million pounds of copper, an increase over our original guidance of 110 to 115 million pounds.”
On October 6, Florence Copper hosted an event in Arizona to mark the onset of commercial production at the world’s first greenfield commercial-scale in-situ copper operation. Representatives of federal, state and local governments attended, including U.S. Environmental Protection Agency (EPA) Administrator Lee Zeldin, along with employees, community and business partners. Administrator Zeldin commented, “After almost two decades without a new copper source anywhere in the U.S., the Florence Copper Mine in Arizona is now open and will produce tens of millions of pounds of copper per year and create hundreds of good-paying jobs to the community. It was great to be there in person yesterday to celebrate the mine’s opening—a huge win for Arizona’s economy and its environment.”
“Bringing Florence Copper into production is a huge accomplishment for our team, and for all of our partners and supporters who made it possible,” Mr. McDonald said. “Florence Copper brings Trekor one step closer to its goal of becoming a leading North American copper producer.”
On October 8, Trekor is hosting an analyst and investor site tour at Florence Copper. The presentation, which provides an overview of the in-situ copper operation and an update on the production ramp-up, can be found on Trekor’s website at: Trekor Metals | Corporate Presentations
For further information on Trekor, see the Company’s website at trekormetals.com or contact:
Investor Enquiries: Brian Bergot, Vice President, Investor Relations – 778-373-4533 or toll-free 1-877-441-4533
Stuart McDonald President and CEO
No regulatory authority has approved or disapproved of the information contained in this news release
Caution Regarding Forward-Looking Information
This document contains “forward-looking statements” that were based on Trekor’s expectations, estimates and projections as of the dates as of which those statements were made. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “outlook”, “anticipate”, “project”, “target”, “believe”, “estimate”, “expect”, “intend”, “should” and similar expressions.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These included but are not limited to:
uncertainties about the future market price of copper and the other metals that we produce or may seek to produce;
changes in general economic conditions, the financial markets and in the market price for our input costs including due to inflationary impacts, such as diesel fuel, acid, steel, concrete, electricity and other forms of energy, mining equipment, and fluctuations in exchange rates, particularly with respect to the value of the U.S. dollar and Canadian dollar, and the continued availability of capital and financing;
inherent risks associated with mining operations, including our current mining operations at Gibraltar and Florence Copper, and their potential impact on our ability to achieve our production estimates;
our high level of indebtedness and its potential impact on our financial condition and the requirement to generate cash flow to service our indebtedness and refinance such indebtedness from time to time;
any increases in interest rates may increase our borrowing costs and impact the profitability of our operations;
the amounts we are required to pay for our acquisition of Cariboo will increase with higher copper prices;
the risk of inadequate insurance or inability to obtain insurance to cover our business risks;
uncertainties related to the accuracy of our estimates of Mineral Reserves (as defined below), Mineral Resources (as defined below), production rates and timing of production, future production and future cash and total costs of production and milling;
the risk that we may not be able to expand or replace Mineral Reserves as our existing Mineral Reserves are mined;
the risk that the ramp-up of the Florence Copper commercial production facility does not proceed within projected timelines or cost estimates, or that initial operations do not achieve results consistent with the projections in the Florence Copper Technical Report, including with respect to operating costs, revenue, sustaining capital, rates of return and cash flows from operations;
our ability to comply with all conditions imposed under the APP and UIC permits for the operation of Florence Copper;
the availability of, and uncertainties relating to, any additional financing necessary for the continued ramp-up and commercial operation of Florence Copper, including with respect to our ability to obtain any additional financing, if needed, to continue and expand commercial operations at Florence Copper;
shortages of water supply, critical spare parts, acid, diesel, maintenance service and new equipment and machinery or our ability to manage surplus water on our mine sites may materially and adversely affect our operations and development projects;
our ability to comply with the extensive governmental regulation to which our business is subject;
uncertainties related to our ability to obtain necessary title, licenses and permits for our development projects and project delays due to third party opposition;
uncertainties related to Indigenous people’s claims and rights, and legislation and government policies regarding the same;
our reliance on the availability of infrastructure necessary for development and on operations, including on rail transportation and port terminals for shipping of our copper concentrate production from Gibraltar, and rail transportation and power for the feasibility of our other British Columbia development projects;
uncertainties related to unexpected judicial or regulatory proceedings;
changes in, and the effects of, the laws, regulations and government policies affecting our exploration and development activities and mining operations;
potential changes to the mineral tenure system in British Columbia, which is undergoing reform including for compliance with the British Columbia Declaration on the Rights of Indigenous Peoples Act (“DRIPA”);
our dependence solely on our 100% interest in Gibraltar and in due course, Florence Copper for our revenues and our operating cash flows;
our ability to extend existing concentrate off-take agreements and cathode purchase agreements or enter into new agreements;
environmental issues and liabilities associated with mining including processing and stockpiling ore;
labour strikes, work stoppages, or other interruptions to, or difficulties in, the employment of labour in markets in which we operate mines, industrial accidents, equipment failure or other events or occurrences, including third party interference that interrupt the production of minerals in our mines;
environmental hazards and risks associated with climate change, including the potential for damage to infrastructure and stoppages of operations due to extreme cold, extreme heat, forest fires, flooding, drought, earthquakes or other natural events in the vicinity of our operations;
litigation risks and the inherent uncertainty of litigation;
our actual costs of reclamation and mine closure may exceed our current estimates of these liabilities;
our ability to renegotiate our existing union agreement for Gibraltar when it expires in May 2027;
the capital intensive nature of our business both to sustain current mining operations and to develop any new projects;
our ability to develop new mining projects in British Columbia may be impacted by joint decision-making and consent agreements being implemented by the Government of British Columbia with First Nations under DRIPA;
The ability to develop the New Prosperity Project is subject to the restrictions set out in our June 2025 Tripartite Agreement with the Province of British Columbia and the Tŝilhqot’in Nation (the “Teẑtan Biny Agreement”), under which the New Prosperity Project is subject to a land use planning process with the Province of British Columbia and we are not permitted to be the proponent of any development of the New Prosperity Project;
our reliance upon key personnel;
the competitive environment in which we operate;
the effects of forward selling instruments to protect against fluctuations in copper prices and other input costs including diesel and acid;
the risk of changes in accounting policies and methods we use to report our financial condition, including uncertainties associated with critical accounting assumptions and estimates;
uncertainties relating to the war in Ukraine, the escalating military conflict involving Iran and broader Middle East instability, and other future geopolitical events including social unrest, which could disrupt financial markets, commodity markets, supply chains, the price and availability of energy, availability of materials and equipment and execution timelines for any project development;
uncertainties relating to the delivery of oil through the Strait of Hormuz resulting from Middle East instability, which could have an adverse effect on global economic activity and potentially increase operating costs generally and reduce global demand for copper, and have a material adverse effect on our business, operations, and the feasibility of our development projects;
changes to U.S. trade policies and tariff measures, including retaliatory tariffs imposed or threatened by Canada and other trading partners, may adversely impact overall economic conditions, copper markets, supply chains, metal prices and input costs; and
other risks detailed from time-to-time in our annual information forms, annual reports, MD&A, quarterly reports and material change reports filed with and furnished to securities regulators, and those risks which are discussed under the heading “Risk Factors”.
For further information on Trekor, investors should review the Company’s annual report on Form 40-F filed with the United States Securities and Exchange Commission and available at www.sec.gov and home jurisdiction filings that are available at www.sedarplus.ca.
NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that the Company will host an investor presentation on October 21, 2026.
Discussion topics will include HLP003, the Company’s proprietary NSA in Phase 3 development for the adjunctive treatment of major depressive disorder (“MDD”), and HLP004, its proprietary NSA in Phase 2 development for generalized anxiety disorder (“GAD”). The presentation will also include key opinion leaders’ perspectives on the current and evolving depression and anxiety treatment landscape, and a question-and-answer session with members of Helus Pharma’s executive leadership team.
The live webcast will take place on Wednesday, October 21, 2026 at 9:00 a.m. EDT. To access the webcast, please click here or visit the Events & Presentation page of Helus Pharma’s website. The archived webcast will be available on the Company’s website on the Events & Presentations page following the presentation.
About Helus Pharma
Helus Pharma Inc. is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
Helus Pharma is working to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of MDD that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for GAD. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to host an investor presentation; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company’s operations; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three months ended June 30, 2026 and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
Neither Cboe Canada nor the Nasdaq Global Market stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. Investor Contact: Matthew Beck astr partners Managing Partner (917) 415-1750 Matthew.beck@astrpartners.com
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration
Expands CNSide contracted payer access to approximately 164 million covered lives
HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has entered into an in-network ancillary provider agreement with Blue Cross and Blue Shield of Florida, Inc. (Florida Blue), effective October 1, 2026.
The agreement establishes contracted reimbursement for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test as well as CNSide® CSF Molecular Profile tests for solid tumors and hematologic malignancies involving the central nervous system. It is the first CNSide payer agreement to include both tumor cell enumeration and molecular profiling.
The Florida Blue agreement adds approximately 6 million covered lives to CNSide’s contracted payer footprint. Combined with previously announced payer agreements, CNSide has now established in-network agreements representing approximately 164 million commercial and Medicare Advantage covered lives, reflecting continued execution of the Company’s national reimbursement strategy.
“This agreement with Florida Blue represents an important milestone in CNSide’s commercial trajectory,” said Marc Hedrick, M.D., Cerenome’s President and Chief Executive Officer. “By expanding contracted reimbursement to both cellular and molecular CSF testing, we are advancing CNSide as a broader CSF diagnostics platform for CNS oncology, combining tumor-cell analysis and molecular profiling to better characterize and monitor cancers involving the central nervous system.”
The Florida Blue agreement expands the scope of CNSide’s contracted reimbursement beyond tumor cell detection in leptomeningeal metastases to include molecular profiling of CNS malignancies. CNSide® CSF Molecular Profile – Solid Tumor provides DNA and RNA molecular profiling of CSF for patients with suspected or confirmed primary CNS tumors or solid tumors metastatic to the CNS, including brain and leptomeningeal metastases. CNSide® CSF Molecular Profile – Hematologic Malignancy provides DNA and RNA molecular profiling of CSF for patients with suspected or confirmed hematologic malignancies involving the CNS. CNSide® CSF Molecular Profile tests are now commercially available through CNSide.
The DNA and RNA CSF molecular profiling approach underlying CNSide® CSF Molecular Profile was recently evaluated in a peer-reviewed, real-world study of 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS, published in The Journal of Liquid Biopsy.
The clinical utility of CNSide CSF tumor cell analysis in leptomeningeal metastases is supported by evaluation in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience. Since 2020, more than 11,000 CNSide® tests have been performed at more than 120 U.S. cancer institutions, supporting clinical decision-making across academic and community oncology practices nationwide.
About Florida Blue Driven by its mission of helping people and communities achieve better health, Florida Blue is the leading health insurer in Florida, and part of GuideWell, a not-for-profit health solutions company. Florida Blue offers a range of health plans and personalized care programs for individuals, families, businesses of all sizes, and Medicare beneficiaries. For over 80 years, the organization has been member centric and committed to making health care as accessible and affordable as possible. Serving more than six million members across all 67 Florida counties, Florida Blue has more than 7,000 employees, is headquartered in Jacksonville, Fla., is owned by its policyholders, and is an independent licensee of the Blue Cross Blue Shield Association.
About CNSide Diagnostics, LLC CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes cerebrospinal fluid (CSF)-based diagnostic tests for cancers involving the central nervous system. The CNSide® CSF diagnostics platform combines cellular analysis, biomarker characterization, and molecular profiling to support the detection, characterization, and longitudinal assessment of CNS malignancies. CNSide currently offers CNSide® CSF Tumor Cell Enumeration for patients with suspected or confirmed leptomeningeal metastases and plans to launch CNSide® CSF Molecular Profile tests for molecular characterization of primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS in October 2026. For more information, visit https://www.cnside-dx.com
About Cerenome Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The CNSide® CSF diagnostics platform combines cellular and molecular testing to support the detection, characterization, and longitudinal assessment of cancers involving the CNS. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.
Forward-Looking Statements This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.
